Innovent Bio won the 7th blockbuster variety and 25 innovative drugs exposed

Recently, good news of Innovent Bio has been frequently reported: Pemetinib tablets were approved in mainland China, Lilly ramucirumab was introduced, and revenue in 2021 exceeded 4 billion yuan.
.
.
The company's first innovative drug, PD-1, has a breakthrough in sales 3 billion yuan, 3 new indications are on the way, and the market leading position is stable
.
In addition to the 7 new drugs that have been approved, Innovent currently has 25 new drugs under development, focusing on the 100 billion anti-tumor drug track.
Sepretinib has submitted a marketing application, and 5 new drugs are in the critical clinical stage.
Pipeline fast harvest period
.
On April 6, Innovent announced that Dabotan (pemigatinib) was approved by the State Food and Drug Administration
.
Dabotan was co-developed by Incyte and Innovent, which is responsible for commercialization in mainland China, Hong Kong, Macau and Taiwan
.
The approval for the Chinese mainland market is another important milestone following the approval in Taiwan, China in June 2021, and the approval in Hong Kong, China in January 2022.
Dubtain is also the first selective FGFR receptor cheese approved in China.
amino acid kinase inhibitor
.
PD-1 sales exceeded 3 billion, 3 new indications are on the way Innovent's annual product revenue (100 million yuan) On March 29, Innovent announced its 2021 results
.
According to non-IFRS measurement, the company's total revenue for the year was 4.
261 billion yuan, an increase of 74.
1% over the same period of the previous year, of which product revenue was 4.
001 billion yuan, an increase of 69% year-on-year
.
During the reporting period, Innovent’s commercialized product portfolio expanded to 6 approved drugs, including Daboshu (sintilimab injection), Dayutong (bevacizumab biosimilar), Su Lixin ( Adalimumab biosimilar), Dubva (rituximab biosimilar), Dabta (pemetinib), and Nerik (orebatinib)
.
As the first commercialized product of Innovent Bio, the PD-1 inhibitor Daboshu (sintilimab injection) maintained its leading position in the market, and its sales amount and sales volume continued to grow strongly
.
Daboshu's sales revenue in 2021 will exceed 3 billion yuan, and sales revenue in 2020 will be 2.
29 billion yuan
.
In addition, among the PD-1 mAbs included in the National Medical Insurance Catalog, Tislelizumab and Toripalizumab have disclosed sales data
.
The annual report shows that BeiGene’s tislelizumab sales revenue in 2021 will be US$255 million (over 1.
6 billion yuan, according to the average exchange rate in 2021), a year-on-year increase of 56%; Junshi Bio’s sales of toripalizumab Revenue was 412 million yuan, down 59% year-on-year
.
At present, sintilimab injection has been approved for 4 indications and successfully entered the national medical insurance list, including first-line non-squamous non-small cell lung cancer, first-line squamous non-small cell lung cancer, first-line hepatocellular carcinoma, classic Chikin lymphoma
.
In addition, sintilimab injection has 3 new indication registration applications under review, including first-line esophageal cancer, first-line gastric cancer, and EGFR-mutated non-squamous lung cancer
.
Commercialization ability is outstanding! Won the 7th blockbuster product Since the birth of the first commercial product, the annual product revenue of Innovent Bio has increased from 1 billion yuan to 4 billion yuan in three years.
The company's commercialization capabilities have been continuously verified, and the commercial product portfolio has continued to Expanding
.
The company has actively reached a series of business cooperation with Baoyuan Pharmaceutical, Ascentage Pharmaceutical, Jinfang Pharmaceutical and UNIION to develop or commercialize a variety of innovative and differentiated products
.
On March 28, Innovent announced that it had reached an agreement with Eli Lilly: Innovent acquired the rights to import, sell, promote and distribute Cirana (ramucirumab) and Retsevmo (septinib) in mainland China.
Exclusive post-approval commercialization rights and priority negotiation rights granted to Innovent to enjoy future commercialization rights of Pirtobrutinib (BTK inhibitor) in mainland China
.
Ramucirumab, a fully human IgG1 monoclonal antibody that specifically binds to VEGFR-2, was approved by the State Food and Drug Administration on March 16, becoming the first and only domestically approved treatment for advanced gastric cancer Targeted drugs for second-line therapy
.
According to Eli Lilly's financial report, the sales revenue of ramucirumab in 2021 will be 1.
033 billion US dollars
.
The expansion of strategic cooperation with Eli Lilly this time brings Innovent Bio's seventh approved product and a near-commercial product, while further expanding its rich oncology product pipeline
.
Innovent's commercialized products The maturing of its commercialization capabilities is inseparable from the improvement of Innovent's production capacity and the expansion of the number of employees
.
In terms of production capacity, Innovent Bio has a total production capacity of 60,000 liters of antibodies that can be put into commercialization, providing production capacity assurance and market-competitive cost advantages for the company's commercial products, and further improving the gross profit margin of commercial products
.
In terms of personnel, Innovent has 6,100 employees, including over 1,500 R&D teams, over 1,300 CMC teams, and about 3,000 sales and marketing teams
.
25 new drugs are launched to deeply cultivate the 100 billion anti-tumor drug market In terms of R&D expenditure, Innovent will invest 2.
116 billion yuan in 2021, a year-on-year increase of over 23%
.
From more than 1 billion yuan in 2018 to more than 2 billion yuan in 2021, under the steadily rising R&D expenditure, Innovent Bio has created a rich pipeline of products under development, and has entered a period of rapid harvesting of later pipelines
.
In addition to the 7 products that have been commercialized, Innovent's R&D pipeline mainly has 25 new drugs under development, covering tumor, autoimmunity, metabolism, ophthalmology and other disease fields, including monoclonal antibodies, dual antibodies, CAR-T, and small molecules.
A variety of drug forms, involving CD47, LAG-3, TIGIT, VEGF, CLDN18.
2, BCMA, PI3K and other important targets
.
In addition, the company has more than 80 R&D projects in the preclinical stage
.
Innovent's main research and development of new drugs Tumor and autoimmunity are the disease areas that Innovent focuses on, and the market space for related drugs is huge
.
According to data from Minet.
com, in 2020, the sales of terminal anti-tumor and immunomodulatory agents in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 160 billion yuan, and its sales in the first half of 2021 The amount exceeded 80 billion yuan, a year-on-year increase of 15.
30%
.
Among the 25 new drugs, many products have the potential of First-in-Class or Best-in-Class
.
Among them, Sepretinib has submitted a marketing application and is expected to become the 8th commercialized product of Innovent
.
Selpercatinib, a highly selective and potent inhibitor of transfection-rearranged genes (RET), was acquired by Eli Lilly through its approximately $8 billion acquisition of Loxo Oncology
.
Selpercatinib, approved in the United States in 2020, is the first precision therapy approved specifically for the treatment of cancer patients with RET gene mutations
.
According to Eli Lilly’s financial report, the sales revenue of sapritinib in 2021 will be US$115 million
.
Five new drugs, including IBI344 (ROS1/NTRK inhibitor), IBI376 (PI3Kδ inhibitor), IBI306 (PCSK9 monoclonal antibody), IBI326 (BCMA CAR-T) and IBI310 (CTLA-4 monoclonal antibody), are in key clinical stages and are expected to be released in Filing an NDA in 2022
.
Among them, IBI376 is a potential best-in-class PI3Kδ inhibitor; IBI306 has long-acting potential compared with imported PCSK9 inhibitors; IBI326 is expected to become the first fully human BCMA CAR-T cell therapy reported in China
.
Conclusion After ten years of hard work, Innovent has grown into a leading biopharmaceutical company in China and has handed over a dazzling transcript
.
2022 is the starting point of the company's second decade of development.
Innovent has formulated a clear global innovation strategy and is committed to becoming a global biopharmaceutical company
.
"Take innovation as the cornerstone and take the road of globalization
.
" It is expected that in the next five years, Innovent Bio will achieve product sales revenue of 20 billion yuan and more than 15 commercialized products
.
Data source: Minet database, company announcement Note: The data statistics are as of April 5th, if there are any omissions, please correct me!